AOD-9604
AOD-9604 is an experimental growth-hormone fragment. Clinical obesity research did not establish weight loss, and AOD-9604 is not an approved weight-loss medicine.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Research areas
Evidence matrix
- Molecular identity
- Confirmed
AOD-9604 is the defined C-terminal 176–191 fragment of human growth hormone. A product’s salt, purity and formulation remain product-specific.
- Human research
- Moderate
- Replication
- Single research group
- Clinical endpoints
- Symptom- or function-related
- Safety
- Limited characterization
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
What the source shows
FDA’s review describes, among other evidence, a 536-person study with no significant weight loss versus placebo; the obesity development program was discontinued.
- FDA PCAC: AOD-9604 evaluationRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Research gaps
- ·Limited safety data, possible immunogenicity and lack of demonstrated efficacy prevent a positive benefit–risk assessment.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
Mechanism
A clinically confirmed mechanism producing therapeutic weight loss has not been established.
- FDA PCAC: AOD-9604 evaluationRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Safety has not been adequately studied.
Contraindications and warnings
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Interactions
No reviewed information on this point has been recorded here yet. This does not mean there are no risks or contraindications.
Research gaps
- ·Limited safety data, possible immunogenicity and lack of demonstrated efficacy prevent a positive benefit–risk assessment.
- ·Short profile: not a complete benefit–risk assessment. Unlisted contraindications and interactions are not adequately established in this profile; missing information does not establish safety.
- FDA PCAC: AOD-9604 evaluationRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 2
- FDA PCAC: AOD-9604 evaluationRegulatory source2024
U.S. Food and Drug Administration
Accessed: